Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma’s
Tag: Hikma
Hikma’s Executive Vice Chairman and President of MENA Joins Rakuten Medical’s Board of Directors
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that its Executive Vice Chairman and President of MENA, Mazen Darwazah, has been appointed as
Hikma delivers strong 2023 performance and a positive outlook for 2024
Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2023. The Group reported
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the registration
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360
Hikma continues strong momentum across the Group and upgrades guidance for 2023
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Chief Executive Officer
Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused
Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V.
